1. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients;Geisler;Clin Cancer Res,1998
2. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized doubleblind trial. The Exemestane Study Group;Kaufmann;J Clin Oncol,2000
3. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)–a randomized phase III trial of the EORTC Breast Group;Paridaens;Proc Am Soc Clin Oncol,2004
4. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer;Coombes;N Engl J Med,2004
5. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain diseasefree after two to three years of tamoxifen–updated survival analysis;Coombes;Breast Cancer Res Treat,2004